Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

BACKGROUND: Most thyroid cancers of follicular origin have a favorable outcome. Only a small percentage of patients will develop metastatic disease, some of which will become radioiodine refractory (RAI-R). Important challenges to ensure the best therapeutic outcomes include proper, timely, and appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Capdevila, Jaume, Deandreis, Desiree’, Durante, Cosimo, Leboulleux, Sophie, Luster, Markus, Netea-Maier, Romana, Newbold, Kate, Singer, Susanne, Sykiotis, Gerasimos P, Bartes, Beate, Farnell, Kate, Locati, Laura Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448584/
https://www.ncbi.nlm.nih.gov/pubmed/37429326
http://dx.doi.org/10.1530/ETJ-23-0068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448584/
https://www.ncbi.nlm.nih.gov/pubmed/37429326
http://dx.doi.org/10.1530/ETJ-23-0068

Ejemplares similares